TEST - Catálogo BURRF
   

Mtor inhibition for cancer therapy: past, present and future / edited by Monica Mita, Alain Mita, Eric K. Rowinsky.

Colaborador(es): Tipo de material: TextoTextoEditor: Paris : Springer Paris : Springer, 2016Edición: 1st ed. 2016Descripción: vi, 300 páginas : 16 ilustraciones, 13 ilustraciones en colorTipo de contenido:
  • texto
Tipo de medio:
  • computadora
Tipo de portador:
  • recurso en línea
ISBN:
  • 9782817804927
Formatos físicos adicionales: Edición impresa:: Sin títuloClasificación LoC:
  • RC254-282
Recursos en línea:
Contenidos:
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
Valoración
    Valoración media: 0.0 (0 votos)
No hay ítems correspondientes a este registro

Springer eBooks

Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.

Para consulta fuera de la UANL se requiere clave de acceso remoto.

Universidad Autónoma de Nuevo León
Secretaría de Extensión y Cultura - Dirección de Bibliotecas @
Soportado en Koha